Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.60 |
| ▸ | OPA1 | O60313 | 1/20 | 0.56 |
| ▸ | EIF5B | O60841 | 1/20 | 0.56 |
| ▸ | MET | P08581 | 1/20 | 0.56 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 5/20 | 0.50 |
| ▸ | CCND1 | P24385 | 5/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 2/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 5/20 | 0.43 |
| ▸ | PRKCH | P24723 | 5/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.43 |
| ▸ | PRKCB | P05771 | 4/20 | 0.43 |
| ▸ | PRKACA | P17612 | 4/20 | 0.43 |
| ▸ | PRKACG | P22612 | 4/20 | 0.43 |
| ▸ | PRKACB | P22694 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1395793 | 0.88 | OPA1 (0.52) | SIRT2SIRT1OPA1EIF5BMET | |
| SCHEMBL224940 | 0.87 | CDK4 (0.61) | SIRT2OPA1EIF5BMETHMOX2 | |
| SCHEMBL6329959 | 0.84 | CDK4 (0.60) | SIRT2OPA1EIF5BMETHMOX2 | |
| SCHEMBL2881681 | 0.83 | CDK4 (0.54) | SIRT2OPA1EIF5BMETHMOX2 | |
| SCHEMBL15348911 | 0.82 | OPA1 (0.53) | OPA1EIF5BMETHMOX2CDK4 | |
| SCHEMBL1395789 | 0.82 | CCNT1 (0.50) | SIRT2CDK4CCND1CCNT1CDK9 | |
| SCHEMBL2879802 | 0.82 | OPA1 (0.52) | SIRT2SIRT1OPA1EIF5BMET | |
| SCHEMBL2875778 | 0.82 | OPA1 (0.52) | SIRT2OPA1EIF5BMETHMOX2 | |
| SCHEMBL2343710 | 0.81 | CDK4 (0.63) | SIRT2OPA1EIF5BMETHMOX2 | |
| SCHEMBL2018580 | 0.79 | OPA1 (0.53) | SIRT2SIRT1OPA1EIF5BMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9642847-B2 | Combinational compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2016-12-08 | — | — | US | disclosed |
| US-9447088-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. | 2015-11-19 | — | — | US | disclosed |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. | 2014-07-17 | — | — | US | disclosed |
| US-8754078-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| US-8377927-B2 | Compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-7713969-B2 | (+)-cis-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2,5-dione; lung, colon, breast, pancreatic, prostate cancers, chronic myelogenous leukemia, melanoma, or ovarian cancer | ARQULE, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-6867198-B2 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297075-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | SIRT2 1948/4885SIRT1 2179/4885OPA1 218/4885 |
| US-20150328208-A1 | COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | TP53, MKI67, POLI | SIRT2 1948/4885SIRT1 2179/4885OPA1 218/4885 |
| US-20140200199-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | SIRT2 1372/4885SIRT1 1500/4885OPA1 88/4885 |
| US-20160355515-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | MKI67, NUP205, TP53 | SIRT2 1372/4885SIRT1 1500/4885OPA1 88/4885 |
| US-20100221251-A1 | Compositions and Methods for Treatment of Cancer | PDCD5, TP53, NUP205 | SIRT2 1005/4885SIRT1 1012/4885OPA1 27/4885 |
| US-20130150310-A1 | Compositions and Methods for Treatment of Cancer | MKI67, NUP205, TP53 | SIRT2 1372/4885SIRT1 1500/4885OPA1 88/4885 |
| US-20030229026-A1 | Agents and methods for the treatment of proliferative diseases | MKI67, CDKN1A, CDK1 | SIRT2 2201/4885SIRT1 1734/4885OPA1 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.